Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study

Abstract Background Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient’s prognosis. To establish individualized EBRT for bone metastases, we investigated factors that affect the local control (LC) of bone metastases. Methods Between January 2010 and December 2019, 536 patients received EBRT for 751 predominantly osteolytic bone metastases. LC at EBRT sites was evaluated with a follow-up computed tomography. The median EBRT dose was biologically effective dose (BED10) (39.0) (range of BED10: 14.4–71.7 Gy). Results The median follow-up time and median time of computed tomography follow-up were 11 (range 1–123) months and 6 (range 1–119) months, respectively. The 0.5- and 1-year overall survival rates were 73% and 54%, respectively. The 0.5- and 1-year LC rates were 83% and 79%, respectively. In multivariate analysis, higher age (≥ 70 years), non-vertebral bone metastases, unfavorable primary tumor sites (esophageal cancer, colorectal cancer, hepatobiliary/pancreatic cancer, renal/ureter cancer, sarcoma, melanoma, and mesothelioma), lower EBRT dose (BED10 < 39.0 Gy), and non-administration of bone-modifying agents (BMAs)/antineoplastic agents after EBRT were significantly unfavorable factors for LC of bone metastases. There was no statistically significant difference in the LC between BED10 = 39.0 and BED10 > 39.0 Gy. Conclusions Regarding tumor-related factors, primary tumor sites and the sites of bone metastases were significant for the LC. As for treatment-related factors, lower EBRT doses (BED10 < 39.0 Gy) and non-administration of BMAs/antineoplastic agents after EBRT were associated with poor LC. Dose escalation from BED10 = 39.0 Gy did not necessarily improve LC.

Download Full-text

In-room computed tomography–based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study

Journal of Radiation Research ◽

10.1093/jrr/rrw121 ◽

2016 ◽

Vol 58 (4) ◽

pp. 543-551 ◽

Cited By ~ 20

Author(s):

Tatsuya Ohno ◽

Shin-Ei Noda ◽

Noriyuki Okonogi ◽

Kazutoshi Murata ◽

Kei Shibuya ◽

...

Keyword(s):

Computed Tomography ◽

Cervical Cancer ◽

Overall Survival ◽

Local Control ◽

External Beam Radiotherapy ◽

Clinical Stage ◽

Stage Ii ◽

High Dose ◽

Significant Difference ◽

Grade 3

Abstract Herein, we investigate the long-term clinical outcomes for cervical cancer patients treated with in-room computed tomography–based brachytherapy. Eighty patients with Stage IB1–IVA cervical cancer, who had undergone treatment with combined 3D high-dose rate brachytherapy and conformal radiotherapy between October 2008 and May 2011, were retrospectively analyzed. External beam radiotherapy (50 Gy) with central shielding after 20–40 Gy was performed for each patient. Cisplatin-based chemotherapy was administered concurrently to advanced-stage patients aged ≤75 years. Brachytherapy was delivered in four fractions of 6 Gy per week. In-room computed tomography imaging with applicator insertion was performed for treatment planning. Information from physical examinations at diagnosis, and brachytherapy and magnetic resonance imaging at diagnosis and just before the first brachytherapy session, were referred to for contouring of the high-risk clinical target volume. The median follow-up duration was 60 months. The 5-year local control, pelvic progression-free survival and overall survival rates were 94%, 90% and 86%, respectively. No significant differences in 5-year local control rates were observed between Stage I, Stage II and Stage III–IVA patients. Conversely, a significant difference in the 5-year overall survival rate was observed between Stage II and III–IVA patients (97% vs 72%; P = 0.006). One patient developed Grade 3 late bladder toxicity. No other Grade 3 or higher late toxicities were reported in the rectum or bladder. In conclusion, excellent local control rates were achieved with minimal late toxicities in the rectum or bladder, irrespective of clinical stage.

Download Full-text

PROSPECTIVE RANDOMIZED STUDY ON TWO DOSE FRACTIONATION REGIMENS OF HIGH DOSE RATE BRACHYTHERAPY FOR CARCINOMA CERVIX: COMPARISON OF CLINICAL RESPONSE AND COMPLICATIONS IN ORGANS AT RISK

SRMS Journal of Medical Science ◽

10.21761/jms.v2i01.10841 ◽

2017 ◽

Vol 2 (01) ◽

Author(s):

Saurabh Goswami ◽

Piyush Kumar ◽

Arvind Kumar Chauhan ◽

Jitendra Nigam ◽

D. P. Singh

Keyword(s):

External Beam Radiotherapy ◽

Equivalent Dose ◽

Dose Fractionation ◽

External Beam ◽

Cancer Cervix ◽

Significant Difference ◽

Group A ◽

The Mean ◽

Group B

Introduction: Cancer Cervix is treated with a combination of external beam radiotherapy and intracavitary brachytherapy. With the recent American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix, at least Equivalent Dose 2 > 80 Gy for patients with complete response or partial response with residual disease less than 4cm is recommended. For non responders or those with tumors larger than 4cm at the time of brachytherapy, tumor dose escalation to an Equivalent Dose 2 of 85-90 Gy is recommended to point A. Present study was designed to see the feasibility of these guidelines in terms of local tumor control and toxicities to rectum and bladder in our group of patients. Material and Methods: Fifty patients of biopsy proven cancer cervix were enrolled. After pre-treatment evaluation all patients were delivered external beam radiotherapy 50 Gy in 25 fractions at 200 cGy/day with concurrent cisplatin on weekly basis. Patients were then randomized into three applications (Group A), four applications (Group B) of HDR Brachytherapy of 6 Gy each so that total treatment time does not exceed 8 weeks. BED and LQED were calculated and assessment of response and complications were assessed. Statistical analysis was done using Chi square test. Results: Mean age of the patients was 50 years. No significant hematological toxicities and radiation reactions were seen during external beam radiotherapy. The mean BED of group A for tumor, rectum and bladder was 137.3 Gy, 112.53 Gy and 103.23 Gy respectively and of group B was 155.3 Gy, 120.98 Gy and 111.95 Gy respectively. The mean EQD2 in group A at tumor, rectum and bladder was 74 Gy, 54.08 Gy and 61.94 Gy respectively and in group B was 82 Gy, 59.18 Gy, and 66.60 Gy respectively. There was no statistically significant difference in local response and early and late bladder reactions in both the groups. Conclusion: In a follow up of six months we did not find any significant difference in toxicities of rectum and bladder. Long term follow up is needed to see for late rectal and bladder toxicities.

Download Full-text

Comparison of stereotactic body radiotherapy and conventional external beam radiotherapy in renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.7_suppl.434 ◽

2015 ◽

Vol 33 (7_suppl) ◽

pp. 434-434 ◽

Cited By ~ 1

Author(s):

Christopher L. Tinkle ◽

Stephen Lawrence Shiao ◽

Vivian K. Weinberg ◽

Amy M. Lin ◽

Alexander R. Gottschalk

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Local Control ◽

Stereotactic Body Radiotherapy ◽

Renal Cell ◽

External Beam Radiotherapy ◽

Local Treatment ◽

Multivariable Analysis ◽

External Beam ◽

Significant Difference

434 Background: Renal cell carcinoma (RCC) is considered a radiation-resistant histology, often with poor response to conventionally fractionated external beam radiotherapy (EBRT). We compared outcomes for patients treated with EBRT versus stereotactic body radiotherapy (SBRT) for RCC. Methods: From 2004 and 2012, a total of 89 patients were treated with either EBRT or SBRT and retrospectively reviewed. Patients with locally recurrent RCC, bone or soft tissue RCC metastases, or primary RCC in a solitary kidney were included. 51 patients received EBRT, while 38 patients received SBRT. The median biologically effective dose (BED), assuming an α/β ratio of 10, was 32.6 Gy10 for the EBRT group and 48.0 Gy10 for the SBRT group. Local failure (LC) was defined pathologically or by imaging according to RECIST 1.1 and toxicity reported according to CTCAE v4.0 guidelines. Univariable and multivariable analyses using Cox’s regression model was performed to determine predictors of local control. Results: Median follow up from RT was 9.8 mo (range: <1-73 mo) with EBRT and 19.7 mo (range: <1-61 mo) with SBRT (p=0.26). EBRT patients were younger (p=0.02) and more were M1 (p=0.04), yet other baseline features did not differ significantly. Total RT dose, dose/fraction, and BED10 were significantly higher in the SBRT group (p≤0.002 for each), while number of fractions was significantly fewer (p<0.001). The 1-year LC estimate was 88% (95% CI, 72-96%) with SBRT and 50% (95% CI, 32-65%) with EBRT (p=0.001), with no significant difference in rate of distant recurrences (p=0.37). The 1-year progression free survival (PFS) and overall survival (OS) between the EBRT and SBRT groups were 17% (95% CI, 8-29%) vs. 39% (95% CI, 24-54%) (p=0.06) and 39% (95% CI, 25-52%) vs. 82% (95% CI, 65-91%) (p=0.002), respectively. The use of SBRT was the most important independent factor significantly predictive of local control on multivariable analysis (p=0.001, LLR test; HR=0.29, 95% CI, 0.13-0.61), while neither age nor metastasis at diagnosis was predictive. No drade 3-4 toxicity was observed in either RT group. Conclusions: The data support that SBRT improves local control over standard fractionation schemes. Higher dose per fraction, with a BED in the range of 48 Gy10, is a safe and effective local treatment modality for RCC.

Download Full-text

Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy.

Journal of Clinical Oncology ◽

10.1200/jco.1990.8.9.1536 ◽

1990 ◽

Vol 8 (9) ◽

pp. 1536-1542 ◽

Cited By ~ 29

Author(s):

L Mandell ◽

F Ghavimi ◽

T Peretz ◽

M LaQuaglia ◽

P Exelby

Keyword(s):

Local Control ◽

Primary Tumor ◽

External Beam Radiotherapy ◽

Local Control Rate ◽

Cancer Center ◽

Radiation Doses ◽

Free Survival ◽

Conventional Fractionation ◽

Childhood Rhabdomyosarcoma

In an attempt to evaluate the radiocurability of microscopic disease in childhood rhabdomyosarcoma (RMS) with total tumor doses of less than 4,000 cGy, we performed a retrospective analysis of all patients with microscopic residual RMS who were treated at the Memorial Sloan-Kettering Cancer Center (MSKCC) during the years 1970 to 1987. There were 32 patients ranging in age from 3 months to 22 years (median, 6 years) with microscopic residual of either (1) a localized primary tumor (MSKCC, stage IB; Intergroup Rhabdomyosarcoma Study [IRS] group IIA), 19 patients; or (2) an involved lymph node region with the primary tumor completely resected (MSKCC stage III; IRS group IIC), 13 patients. Twenty-nine of the 32 patients presented with embryonal histology. All patients were treated with combination chemotherapy (CT) and megavoltage external beam radiotherapy (RT). The RT was delivered in either conventional fractionation of 180 to 200 cGy daily (30 patients) or hyperfractionation of 150 cGy twice daily (two patients). Fifteen patients received RT doses of less than 4,000 cGy with a range of 3,000 to 3,600 cGy and a median value of 3,100 cGy; 17 patients received 4,000 cGy or more with a range of 4,000 to 6,000 cGy and a median value of 4,600 cGy. With a median follow-up of 11 years, the relapse-free survival was 25 of 32 patients (less than 4,000 cGy, 12 of 15; greater than or equal to 4,000 cGy, 13 of 17). The RT local control rate was 30 of 32 (less than 4,000 cGy, 14 of 15; greater than or equal to 4,000 cGy, 16 of 17 [P = .94]). Our results suggest that radiation doses of below 4,000 cGy, when combined with effective multiagent CT, may be sufficient for local control of microscopic disease in childhood embryonal RMS.

Download Full-text

External Beam Radiotherapy With Endocavitary Boost for Nasopharyngeal Cancer: Treatment Results and Late Toxicity After Extended Follow-Up

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2009.08.072 ◽

2010 ◽

Vol 78 (3) ◽

pp. 689-695 ◽

Cited By ~ 15

Author(s):

Dominic A.X. Schinagl ◽

Henri A.M. Marres ◽

Arnoud C. Kappelle ◽

Matthias A.W. Merkx ◽

Lucas A.M. Pop ◽

...

Keyword(s):

Cancer Treatment ◽

External Beam Radiotherapy ◽

Nasopharyngeal Cancer ◽

Late Toxicity ◽

External Beam ◽

Treatment Results

Download Full-text

UNALTERED IMAGE OF HEALTH MAINTENANCE: AN OBSERVATION OF NON-PARTICIPANTS IN A SWEDISH COHORT STUDY OF 85 TO 86 YEAR OLDS

Journal of Frailty & Aging ◽

10.14283/jfa.2015.47 ◽

2015 ◽

pp. 1-7

Author(s):

H.-J. DONG ◽

E. WRESSLE ◽

J. MARCUSSON

Keyword(s):

Home Visit ◽

Hospital Admissions ◽

Clinic Visit ◽

Old People ◽

Related Factors ◽

Health Maintenance ◽

Very Old ◽

Significant Difference ◽

Sheltered Accommodation

Background: Selection bias is often inevitable in epidemiologic studies. It is not surprising that study conclusions based on participants’ health status are frequently questioned. Objective: This study aimed to assess whether the non-participants affected the characteristics of a general population of the very old people. Design, Setting and Participants: Prospective, cross-sectional (N=650, aged 85 years old) analysis and 1-year follow-up (n=273), in Linköping, Sweden. Measurements: We analysed data on health-related factors from a postal questionnaire, a home visit and a clinic visit at baseline and at the 1-year follow-up. We calculated the effect size to evaluate the degree of differences between the groups. Results: A greater proportion of non-participants resided in sheltered accommodation or nursing homes (participants vs non-response vs refusal, 11% vs 22% vs 40, P<0.001, φ=0.24). During the home visit or clinic visit, a higher proportion of dropouts reported mid-severe problems in EQ-5D domains (mobility and self-care) and limitations in personal activities of daily living, but the differences between participants and dropouts were very small (φ<0.2). No significant difference was found between the groups with regard to emergency room visits or hospital admissions, despite the fact that more participants than dropouts (φ=0.23) had multimorbidities (≥2 chronic diseases). Living in sheltered accommodation or a nursing home (odds ratio (OR), 2.8; 95% confidence interval (CI), 1.5-5), female gender (OR, 1.8; 95% CI, 1.1-3.1) and receiving more home visits in primary care (OR, 1.03; 95% CI, 1-1.06) contributed positively to drop out in the data collection stages over the study period. Conclusion: Non-participants were not considered to be a group with worse health. Mobility problems may influence very old people when considering further participation, which threatens attrition.

Download Full-text